Gradient Investments’s C4 Therapeutics CCCC Stock Holding History

Gradient Investments’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25	Closed	-$116	–	450
2024 Q2	$116	Buy	+25	New	+$149	﹤0.01%	1301

Other funds holding CCCC

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gradient Investments's CCCC Position: Q3 2024 in Review

Gradient Investments sold out of C4 Therapeutics (CCCC) in Q3 2024, closing a stake of 25 shares — an estimated $116 sold.

Gradient Investments first reported a position in CCCC in Q2 2024 and held it in 1 quarter. The position peaked at $116 in Q2 2024. 118 funds tracked by Wall St. Rank hold CCCC as of Q3 2024.

Gradient Investments reported no remaining C4 Therapeutics position as of Q3 2024 after selling out during the quarter.
Gradient Investments sold 25 C4 Therapeutics shares in Q3 2024, an estimated $116.
Gradient Investments first reported a position in C4 Therapeutics in Q2 2024 and held it in 1 quarter.
Gradient Investments's C4 Therapeutics position peaked at $116 in Q2 2024.
118 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2024.

Based on Gradient Investments's 13F filing for Q3 2024, filed 15 Oct 2024.